Rheumatoid Arthritis in the Elderly
Conditions
Interventions
Intervention group:Tocilizumab 8 mg/kg, administered intravenously over 1 hour, every four weeks for a total of 6 doses
Sponsors
The Second Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Age
60 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. voluntary participation in the study and signing of informed consent; 2. be aged = 60 years, male or female; 3. physician-confirmed diagnosis of rheumatoid arthritis that meets the diagnostic criteria for RA classification established by ACR/EULAR 2010; 4. active RA disease (DAS28 = 2.6); 5. no previous treatment with tolizumab; 6. good compliance and cooperation with follow-up visits.
Exclusion criteria
Exclusion criteria: 1. use of intra-articular or extra-gastrointestinal glucocorticoids for arthritis within 4 weeks prior to screening; 2. immunization with live vaccines within 4 weeks prior to screening; 3. history of underlying tuberculosis infection or tumor; 4. acute or chronic active infection; 5. concomitant other diffuse connective tissue diseases such as systemic lupus erythematosus, severe osteoarthritis of the knee and dry syndrome; 6. severe hepatic and renal insufficiency; 7. severe cardiac, cerebral and vascular pathology; 8. Presence of other conditions that, in the judgment of the investigator, make enrollment inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of clinical remission(CDAI=2.8); | — |
Secondary
| Measure | Time frame |
|---|---|
| DAS28-ESR;EULAR Boolean 2.0;CDAI =10;ACR20/50/70;HAQ-DI;VAS;PtGA;MDGA; | — |
Countries
China
Contacts
Public ContactShen Haili
The Second Hospital of Lanzhou University
Outcome results
None listed